Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th

Rhea-AI Summary

Cortexyme, Inc. (Nasdaq: CRTX) announced that CEO Casey Lynch will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 1:25 p.m. ET. The event will be virtual and accessible via a webcast on the company's Investor Calendar page. Cortexyme specializes in developing therapies targeting infectious pathogens associated with Alzheimer’s disease, particularly P. gingivalis. Their research has been confirmed by multiple labs globally and published in peer-reviewed journals.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Cortexyme, Inc. (Nasdaq: CRTX) announced that Casey Lynch, chief executive officer, co-founder, and chair, will participate in a fireside chat at the 4^th Annual Evercore ISI HealthCONx Conference taking place virtually on Tuesday, November 30, 2021, beginning at 1:25 p.m. Eastern Time.

A webcast of the event will be accessible on the Investor Calendar page under the News & Events heading of Cortexyme’s investor website at ir.cortexyme.com. The webcast will be archived at that location for 90 days.

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Cortexyme’s lead program targets a specific, infectious pathogen called P. gingivalis found in the brain of Alzheimer’s patients and other organs and tied to degeneration and inflammation in humans and animal models. The company’s causation evidence for Alzheimer’s disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005528/en/

Stacy Roughan

Vice President, Corporate Communications & Investor Relations

Cortexyme, Inc.

ir@cortexyme.com

Source: Cortexyme, Inc.

FAQ

When is Cortexyme participating in the Evercore ISI HealthCONx Conference?

Cortexyme is participating in the Evercore ISI HealthCONx Conference on November 30, 2021, at 1:25 p.m. ET.

Who will represent Cortexyme at the conference?

CEO Casey Lynch will represent Cortexyme at the conference.

How can I watch the Cortexyme conference webcast?

The Cortexyme conference webcast can be accessed on their Investor Calendar page on their website.

What is Cortexyme's focus in biopharmaceuticals?

Cortexyme focuses on therapies targeting infectious pathogens linked to Alzheimer’s and other degenerative diseases.

What pathogen does Cortexyme's lead program target?

Cortexyme's lead program targets the infectious pathogen P. gingivalis.